Strides Pharma Scien
Ticker > Company >

Strides Pharma Scien share price

Strides Pharma Science Ltd.

NSE: STAR BSE: 532531 SECTOR: Pharmaceuticals & Drugs  86k   131   31

652.90
-18.35 (-2.73%)
BSE: 06 May 04:01 PM

Price Summary

Today's High

₹ 672.15

Today's Low

₹ 645.2

52 Week High

₹ 1675.25

52 Week Low

₹ 530.7

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 6017.3 Cr.

Enterprise Value

₹ 7499.65 Cr.

No. of Shares

9.22 Cr.

P/E

68.51

P/B

1.7

Face Value

₹ 10

Div. Yield

0.38 %

Book Value (TTM)

₹  383.25

CASH

₹ 111.83 Cr.

DEBT

₹ 1594.18 Cr.

Promoter Holding

28.3 %

EPS (TTM)

₹  9.53

Sales Growth

16.11%

ROE

1.87 %

ROCE

4.77%

Profit Growth

1298.78 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year16.11%
3 Year5.05%
5 Year6.97%

Profit Growth

1 Year1298.78%
3 Year-5.76%
5 Year-9.91%

ROE%

1 Year1.87%
3 Year2.48%
5 Year2.73%

ROCE %

1 Year4.77%
3 Year2.84%
5 Year3.58%

Debt/Equity

0.4481

Price to Cash Flow

-168.29

Interest Cover Ratio

1.4146

CFO/PAT (5 Yr. Avg.)

0.765681390851817

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 28.30 51.98
Dec 2024 26.82 54.25
Sep 2024 25.84 49.17
Jun 2024 25.86 64.65
Mar 2024 25.88 72.70
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company’s PEG ratio is 0.0537565671745343.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.44755687213534.

 Limitations

  • The company has shown a poor profit growth of -5.75660412141952% for the Past 3 years.
  • The company has shown a poor revenue growth of 5.04701712407989% for the Past 3 years.
  • Company has a poor ROE of 2.47698991797854% over the past 3 years.
  • Company has a poor ROCE of 2.83846342205997% over the past 3 years
  • Company has high debtor days of 238.695.
  • Company has negative cash flow from operations of -35.756.
  • Tax rate is low at 5.9321.
  • The company is trading at a high PE of 68.51.
  • Promoter pledging is high as 51.98%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 379.64 617.63 554.75 609.96 550.92
Total Expenditure 378.17 526.84 493.72 546.93 476.82
Operating Profit 1.47 90.79 61.03 63.03 74.1
Other Income 4.9 29.63 11.83 23.55 2.43
Interest 36.24 46.77 46.88 50.15 34.21
Depreciation 21.52 20.81 20.32 21.98 20.92
Exceptional Items -5.29 -0.07 0 -0.01 -0.02
Profit Before Tax -56.69 52.78 5.66 14.43 21.38
Tax 3.6 -0.89 1.75 -0.88 6.44
Profit After Tax -60.29 53.66 3.92 15.31 14.94
Adjusted EPS (Rs) -6.56 5.84 0.43 1.66 1.62

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1691.93 1857.57 1979 1854.5 2153.26
Total Expenditure 1487.48 1698.34 1902.37 1771.77 1905.95
Operating Profit 204.46 159.23 76.63 82.72 247.31
Other Income 93.07 117.09 123.49 99.82 80.28
Interest 66.84 65.34 74.24 138.68 167.93
Depreciation 94.24 99.34 104.37 93.62 84.67
Exceptional Items 0 0 0 -15 -5.37
Profit Before Tax 136.45 111.64 21.51 -64.76 69.62
Tax 16.17 33.4 -158.68 -69.44 4.13
Net Profit 120.28 78.24 180.19 4.68 65.49
Adjusted EPS (Rs.) 13.43 8.72 20.07 0.52 7.13

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 89.57 89.68 89.79 90.3 91.9
Total Reserves 3069.22 3158.38 3316.89 3364.75 3469.22
Borrowings 0 147.54 124.7 284.74 196.99
Other N/C liabilities -37.31 159.89 -16.42 -12.12 -7.12
Current liabilities 1454.95 1590.64 1841.32 1796.83 1995.3
Total Liabilities 4576.42 5146.12 5356.28 5524.5 5746.29
Assets
Net Block 578.35 576.66 604.09 584.3 544.58
Capital WIP 89.47 81.36 30.45 15.79 57.71
Intangible WIP 22.78 29.31 25.26 39.59 36.29
Investments 2170.55 2394.65 2399.76 2491.77 2498.34
Loans & Advances 237.42 247.33 304.95 245.47 174.39
Other N/C Assets 83.82 72.96 16.51 21.18 19.13
Current Assets 1394.03 1743.86 1975.25 2126.4 2415.86
Total Assets 4576.42 5146.12 5356.28 5524.5 5746.29
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 136.45 111.64 21.51 -64.76 69.62
Adjustment 130.28 114.15 75.17 172.87 215.99
Changes in Assets & Liabilities -96.91 -109.81 -400.77 33.81 -375.08
Tax Paid -32.18 166.79 21.41 99.82 53.71
Operating Cash Flow 137.64 282.76 -282.69 241.74 -35.76
Investing Cash Flow 62.83 -275.64 18.78 -182.58 -61.27
Financing Cash Flow -203.56 -48.64 250.73 10.82 107.62
Net Cash Flow -3.09 -41.52 -13.18 69.98 10.6

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 25.88 25.86 25.84 26.82 28.30
aditya arun kumar 0.06 0.06 0.06 0.06 0.06
agraganya private trust (... - - - 0.33 0.33
ambemata securities (vima... - - - - 0.26
anuradha k r 0.01 0.01 0.01 0.01 0.01
arun kumar pillai 2.11 2.11 2.11 2.13 2.24
hemalatha pillai 0.07 0.07 0.07 0.07 0.07
k r lakshmi 0.14 0.14 0.14 0.14 0.14
k r ravishankar 1.37 1.37 1.37 1.36 1.36
karuna business solutions... 3.51 3.51 3.51 3.50 3.50
padmakumar karunakaran pi... 0.20 0.20 0.20 0.20 0.20
pronomz ventures llp 17.18 17.18 17.17 18.22 19.58
rajitha gopalakrishnan 0.07 0.07 0.07 0.07 0.07
sajitha pillai 0.10 0.10 0.10 0.10 0.10
shasun enterprises llp (f... - - - 0.17 0.17
vineetha mohanakumar pill... 0.21 0.21 0.21 0.21 0.21
ambemata securities 0.26 0.26 0.26 0.26 -
agraganya private trust 0.33 0.33 0.33 - -
shasun enterprises llp 0.26 0.24 0.24 - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 74.12 74.14 74.16 73.18 71.70
authum investment and inf... - - - - 1.11
axis mutual fund trustee ... - - - 1.54 1.24
bnp paribas financial mar... - - 1.12 1.33 1.31
investor education and pr... - - - 0.15 0.15
morgan stanley asia (sing... 1.08 1.26 1.35 1.62 2.02
mukul mahavir agrawal 1.63 1.63 1.52 1.16 1.16
oman india joint investme... 1.10 1.10 1.10 1.10 1.10
quant mutual fund - quant... - - 5.41 5.40 5.40
route one fund i, l.p. 2.17 2.17 2.17 2.17 2.17
route one offshore master... 5.06 5.06 5.06 5.05 5.05
satpal khattar 1.70 1.70 1.70 1.60 1.60
sbi life insurance co. lt... - 1.26 2.19 2.23 2.09
vanguard total internatio... - - - - 1.03
aditya birla sunlife trus... - - - 1.43 -
amansa holdings private l... 4.15 4.15 3.87 1.73 -
max life insurance compan... - - 1.32 1.04 -
aditya birla sun life tru... - - 3.35 - -
investor education and pr... 0.15 0.15 0.15 - -
life insurance corporatio... 3.17 2.81 1.91 - -
aditya birla sun life tru... 5.03 4.94 - - -
bnp paribas financial mar... 1.16 1.08 - - -
max life insurance co ltd... - 1.64 - - -
quant mutual fund 5.42 5.42 - - -
max life insurance compan... 1.64 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Strides Pharma Science’s arm acquires identified ANDAs from Nostrum Laboratories, Inc, USA 30 Apr, 11:23 AM Strides Pharma Science's arm incorporates wholly owned subsidiary 11 Apr, 3:00 PM Strides Pharma Science informs about disclosure 19 Mar, 5:36 PM Strides Pharma Science’s board approves demerger of identified business of Arco Lab 19 Mar, 4:23 PM Strides Pharma Science informs about acquisition 15 Mar, 11:30 AM Strides Pharma Science informs about disclosure 19 Feb, 12:10 PM Strides Pharma Scien - Quaterly Results 30 Jan, 1:21 PM Strides Pharma Scien - Quaterly Results 30 Jan, 1:21 PM Strides Pharma Scien - Quaterly Results 30 Jan, 1:21 PM Strides Pharma Science informs about disclosure 23 Jan, 1:00 PM Strides Pharma Science informs about updates 23 Jan, 12:31 PM Strides Pharma Science informs about press release 20 Jan, 5:40 PM Strides Pharma Science informs about press release 20 Jan, 5:05 PM Strides Pharma Science’s arm gets USFDA’s approval for Acetaminophen and Ibuprofen Tablets 20 Jan, 4:42 PM Strides Pharma Science informs about voting results of postal ballot 29 Nov, 5:25 PM Strides Pharma Science informs about allotment of shares 29 Nov, 3:43 PM Strides Pharma Science’s arm to acquire balance 30% stake in Strides Pharma International AG 26 Oct, 11:30 AM Strides Pharma Science gets nod to invest Rs 1.61 crore in AMPIN C&I 24 Oct, 3:30 PM Strides Pharma Scien - Quaterly Results 24 Oct, 1:19 PM Strides Pharma Scien - Quaterly Results 24 Oct, 1:19 PM Strides Pharma Scien - Quaterly Results 24 Oct, 1:19 PM Strides Pharma Science informs about press release 16 Oct, 9:56 AM Strides Pharma Science informs about press release 9 Oct, 5:03 PM Strides Pharma Science’s arm gets USFDA’s approval for Fluoxetine Tabs 16 Sep, 3:30 PM Strides Pharma Science informs about press release 11 Sep, 11:33 AM Strides Pharma Science’ arm gets USFDA’s approval for Theophylline Extended-Release Tablets 6 Sep, 11:17 AM Strides Pharma Science’s arm gets EIR from USFDA 19 Aug, 10:42 AM Strides Pharma Science’s arm to acquire balance 81% stake in Consumer UK 6 Aug, 12:00 PM Strides Pharma Scien - Quaterly Results 29 Jul, 2:05 PM Strides Pharma Scien - Quaterly Results 29 Jul, 2:05 PM Strides Pharma Scien - Quaterly Results 29 Jul, 2:05 PM Strides Pharma Science informs about acquisition 27 Jul, 4:42 PM Strides Pharma Science’s arm incorporates company in New Zealand 27 Jul, 12:05 PM Strides Pharma Science informs about loss of share certificate 16 Jul, 2:35 PM Strides Pharma Scien - Quaterly Results 22 May, 1:43 PM Strides Pharma Scien - Quaterly Results 22 May, 1:43 PM Strides Pharma Scien - Quaterly Results 22 May, 1:43 PM Strides Pharma Science informs about press release 22 May, 12:55 PM Strides Pharma Science’s step-down arm gets USFDA’s approval for Sucralfate Oral Suspension 22 May, 10:30 AM Strides Pharma Science’s arm gets USFDA’s approval for Sevelamer Carbonate Tablets 10 May, 2:08 PM Strides Pharma Science informs about press release 9 Apr, 9:49 AM Strides Pharma Science’s arm gets USFDA’s approval for Fluoxetine Tabs 9 Apr, 9:27 AM Strides Pharma Science informs about company update 6 Apr, 3:13 PM USFDA completes cGMP inspection at Chennai formulations facility of Strides Pharma Science’s arm 6 Apr, 3:02 PM Strides Pharma Science informs about completion of inspection 6 Apr, 1:59 PM Strides Pharma Science informs about disclosure 21 Mar, 12:05 PM Strides Pharma Science’s arm receives USFDA’s approval for Gabapentin Tablets 5 Mar, 3:41 PM Strides Pharma Scien - Quaterly Results 30 Jan, 1:16 PM Strides Pharma Scien - Quaterly Results 30 Jan, 1:16 PM Strides Pharma Scien - Quaterly Results 30 Jan, 1:16 PM

Strides Pharma Scien Stock Price Analysis and Quick Research Report. Is Strides Pharma Scien an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Strides Pharma Scien and its performance over the period of time. Strides Pharma Scien stock price today is Rs 647.9.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Strides Pharma Scien cash from the operating activity was Rs -35.756 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Strides Pharma Scien has a Debt to Equity ratio of 0.4481 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Strides Pharma Scien , the EPS growth was 1274.4069 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Strides Pharma Scien has OPM of 11.4852470070935 % which is a bad sign for profitability.
     
  • ROE: Strides Pharma Scien have a poor ROE of 1.8729 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Strides Pharma Scien is Rs 647.9. One can use valuation calculators of ticker to know if Strides Pharma Scien share price is undervalued or overvalued.
Last Updated on:
Brief about Strides Pharma Scien

Strides Pharma Science Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Strides Pharma Science Ltd. is an Indian multinational pharmaceutical company headquartered in Bangalore, India. The company was founded in 1990 and has since then been a leading player in the global pharmaceutical market. Strides Pharma Science Ltd. has a presence in over 100 countries worldwide and is committed to providing high-quality, affordable healthcare solutions to people around the globe.

Strides Pharma Science Ltd. Share Price

The share price of Strides Pharma Science Ltd. is a key indicator of the company's financial performance. Investors who are looking to invest in the company can keep an eye on the share price and monitor any fluctuations. The share price can also be used to determine the company's market capitalization and valuation, which can be useful in making investment decisions.

Strides Pharma Science Ltd. Balance Sheet

The balance sheet of Strides Pharma Science Ltd. provides a snapshot of the company's financial position at a particular point in time. Investors can use the balance sheet to assess the company's liquidity, solvency, and overall financial health. Our website provides pre-built screening tools that can be used to analyze the balance sheet using various methods such as DCF Analysis, BVPS Analysis, Earnings multiple approach and DuPont analysis.

Strides Pharma Science Ltd. Annual Report

The annual report of Strides Pharma Science Ltd. provides a comprehensive overview of the company's financial performance over the past year. Investors can use the annual report to assess the company's revenue, profits, and expenses. Our website provides the annual report as a downloadable document, which can be accessed by investors and analysts.

Strides Pharma Science Ltd. Dividend

Dividends are an important aspect of any investment. They are a way for shareholders to earn a return on their investment in a company. Strides Pharma Science Ltd. has a history of paying dividends to its shareholders. Investors can track the dividend history of the company on our website and stay updated on any changes.

Strides Pharma Science Ltd. Quarterly Result

The quarterly result of Strides Pharma Science Ltd. provides a detailed analysis of the company's financial performance for a particular quarter. Investors can use the quarterly result to assess the company's revenue, profits, and expenses. Our website provides pre-built screening tools that can be used to analyze the quarterly result using various methods.

Strides Pharma Science Ltd. Stock Price

The stock price of Strides Pharma Science Ltd. is a key indicator of the company's financial performance. Investors can track the stock price on our website and stay updated on any changes. The stock price can also be used to determine the company's market capitalization and valuation, which can be useful in making investment decisions.

Strides Pharma Science Ltd. Price Chart

Price charts are a useful tool for investors who are looking to track the stock price of a company over time. Our website provides price charts for Strides Pharma Science Ltd. that allow investors to analyze the stock price trend over a period of time. The price chart can be used to identify patterns and trends that can be useful in making investment decisions.

Strides Pharma Science Ltd. News

Our website provides the latest news and updates about Strides Pharma Science Ltd. Investors can stay updated on any new developments in the company by regularly checking our news section. The news can provide useful insights into the company's future plans and strategies.

Strides Pharma Science Ltd. Concall Transcripts

Concall transcripts provide a detailed record of the company's conference calls with analysts and investors. Our website provides the concall transcripts for Strides Pharma Science Ltd. as downloadable documents. Investors can use the concall transcripts to gain insights into the company's future plans and strategies.

Strides Pharma Science Ltd. Investor Presentations

Investor presentations provide a detailed overview of the company's financial performance and future plans. Our website provides the investor presentations of Strides Pharma Science Ltd. as downloadable documents. Investors can use the investor presentations to analyze the company's financial health and future prospects.

Strides Pharma Science Ltd. Promoters

Promoters are individuals or entities who hold a significant stake in the company and play an important role in its management. Strides Pharma Science Ltd. has several prominent promoters who have played a key role in the company's growth over the years. Our website provides information about the company's promoters, including their background and their role in the company.

Strides Pharma Science Ltd. Shareholders

Shareholders are individuals or entities who hold shares in the company. Strides Pharma Science Ltd. has a wide range of shareholders, including institutional investors, retail investors, and high net worth individuals. Our website provides information about the company's major shareholders and their stake in the company.

Premium Features

Our website provides several premium features that can be used to analyze the financial performance of Strides Pharma Science Ltd. These features include DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. Investors can use these tools to gain a deeper understanding of the company's financial health and future prospects.

Note: Kindly note that the above content is strictly just for informative purposes and does not attempt to recommend any specific actions or decisions for the investors. We always advise investors to carry out thorough research and consult with financial experts before making any investment decisions. 

Strides Pharma Science Balance Sheet Overview

Strides Pharma Science Equity and Liabilities

Analyzing the balance sheet of Strides Pharma Science reveals a steady growth in Share Capital from Rs Cr. 89.57 in March 2020 to Rs Cr. 91.90 by March 2024. The company has also managed to increase its Total Reserves from Rs Cr. 3,069.22 to Rs Cr. 3,469.22 over the same period, showcasing a robust reserve fund. However, Borrowings have seen fluctuations, peaking in March 2023 at Rs Cr. 284.74 before dropping to Rs Cr. 196.99 in March 2024, indicating changes in financing strategies.

Strides Pharma Science Assets Analysis

On the assets front, there's a noticeable diversification in asset allocation. Investments have grown from Rs Cr. 2,170.55 in March 2020 to Rs Cr. 2,498.34 by March 2024, highlighting the company's focus on increasing its investment portfolio. Meanwhile, Current Assets have seen a significant increase from Rs Cr. 1,394.03 to Rs Cr. 2,415.86, suggesting an enhancement in the company's short-term asset base.

Overall Financial Health of Strides Pharma Science

The data reflects the standalone Balance Sheet of the company, indicating a steady growth in financial stability and asset accumulation over the observed period. It's essential for investors to consider such financial health metrics among other factors like market trends, NSE/BSE indices, and sector performance when screening stocks or evaluating investment opportunities in the pharmaceutical sector.

Read More
X